Source: International Congress 2019 – Airway physiology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Ghebre (London, United Kingdom), A. Bell (London, United Kingdom), A. Mann (London, United Kingdom). Late Breaking Abstract - A key endpoint in viral challenge models of asthma exacerbations. 347

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract: An animal model for studies on pathogenesis and pharmaceutical intervention of chronic asthma Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Late Breaking Abstract - Estimating the relationship between environmental exposures and acute exacerbations of COPD Source: Virtual Congress 2021 – Occupational COVID-19 and respiratory infections Year: 2021 Late Breaking Abstract - Increased type 2 inflammation in patients with asthma post rhinovirus infection Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 CompEx – A novel composite asthma exacerbation endpoint Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015 Childhood asthma and infection: virus-induced exacerbations as determinants and modifiers Source: Eur Respir J 2010; 36: 438 Year: 2010 Late Breaking Abstract - Reimbursement for asthma care is a universal barrier to achieving asthma symptom control: the SABINA III study Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020 Late Breaking Abstract - Exacerbation of asthma in childhood: seasonal pattern and risk factors. Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Late Breaking Abstract - ENose based phenotyping of newly presented patients with asthma or COPD Source: International Congress 2018 – Biomarkers in COPD and asthma Year: 2018 Late Breaking Abstract - Effects of tezepelumab on host epithelial tolerance to virus in patients with uncontrolled asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Late Breaking Abstract - Shared genetic origins of obesity and poor ICS response in children with asthma Source: Virtual Congress 2021 – Lung disease burden and management Year: 2021 Late Breaking Abstract - Azithromycin for acute COPD exacerbations requiring hospitalization – the BACE trial results Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Late Breaking Abstract - Microbiome-driven clusters in severe asthma derived from induced sputum: identification and stability over time. Source: International Congress 2019 – Revealing novel asthma immunopathology endotypes Year: 2019 Late Breaking Abstract - Silent exacerbations: underreporting of COPD exacerbations in Poland Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Association between blood eosinophils and exacerbation risk in COPD primary care Source: International Congress 2017 – COPD: from screening to risk factors of lung cancer Year: 2017 Late Breaking Abstract - Cardiovascular adverse events of drugs targeting IL-5 in severe asthma: a pharmacovigilance study Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020 Late Breaking Abstract - Defining a severe asthma super-responder: findings from a Delphi process Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020